Intellia Therapeutics, Inc.

As of June 30, 2026, Intellia Therapeutics, Inc. carries a market capitalization of 1.75B, placing it among publicly traded companies globally. Its enterprise value stands at 1.45B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Intellia Therapeutics, Inc.'s next confirmed earnings release is scheduled for November 5, 2026.

As of June 30, 2026, Intellia Therapeutics, Inc. has 140.02M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 31.04, and the price-to-book ratio stands at 2.97.

These figures are as of June 30, 2026. The EV/Sales ratio of 30.24 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 1.45B versus a market cap of 1.75B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Intellia Therapeutics, Inc. maintains a current ratio of 6.65, meaning it holds 6.7x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, Intellia Therapeutics, Inc. posted a negative return on equity (ROE) of -55.44, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -45.55, reflecting losses generated across the asset base. The company generates approximately 125,347.41 in revenue per employee across its workforce of 383.50, a quick read on workforce productivity versus industry peers.

As of the close on October 19, 2026, Intellia Therapeutics, Inc.'s stock has declined approximately 43.01% over the past 52 weeks.

Over the twelve months ended June 30, 2026, Intellia Therapeutics, Inc. generated 48.07M in revenue and converted that into -323.11M in net income, yielding earnings per share of -2.70. EBITDA reached -329.79M, while operating income came in at -342.10M.

As of June 30, 2026, Intellia Therapeutics, Inc. holds 353.63M in cash and equivalents against 59.30M in total debt, resulting in a net debt position of -85.73M. Total book value stands at 587.86M, with working capital of 362.26M providing operational flexibility.

Intellia Therapeutics, Inc. produced -280.03M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -1.65M in capital expenditures, free cash flow totaled -281.68M - equivalent to -2.36 per share.

These figures cover the twelve months ended June 30, 2026. The operating margin of -711.66 and net profit margin of -672.16 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -18.88: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -16.01, meaning Intellia Therapeutics, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2026, Intellia Therapeutics, Inc. has an Altman Z-Score of 4.53, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.